Exploiting PRMT5 As a Target for Combination Therapy in Mantle Cell Lymphoma Characterized by Frequent ATM and TP53 Mutations

Overview

Journal Blood Cancer J

Date 2023 Feb 16

PMID 36797243

Authors

Yuxuan Che

Yang Liu

Yixin Yao

Holly A Hill

Yijing Li

Qingsong Cai

Fangfang Yan

Preetesh Jain

Wei Wang

Lixin Rui

Michael Wang

Affiliations

Soon will be listed here.

Abstract

Constant challenges for the treatment of mantle cell lymphoma (MCL) remain to be recurrent relapses and therapy resistance, especially in patients harboring somatic mutations in the tumor suppressors ATM and TP53, which are accumulated as therapy resistance emerges and the disease progresses, consistent with our OncoPrint results that ATM and TP53 alterations were most frequent in relapsed/refractory (R/R) MCL. We demonstrated that protein arginine methyltransferase-5 (PRMT5) was upregulated in R/R MCL, which predicted a poor prognosis. PRMT5 inhibitors displayed profound antitumor effects in the mouse models of MCL with mutated ATM and/or TP53, or refractory to CD19-targeted CAR T-cell therapy. Genetic knockout of PRMT5 robustly inhibited tumor growth in vivo. Co-targeting PRMT5, and ATR or CDK4 by using their inhibitors showed synergistic antitumor effects both in vitro and in vivo. Our results have provided a rational combination therapeutic strategy targeting multiple PRMT5-coordinated tumor-promoting processes for the treatment of R/R MCL with high mutation burdens.

Citing Articles

Therapeutic targeting potential of the protein lysine and arginine methyltransferases to reverse cancer chemoresistance.

Micallef I, Fenech K, Baron B Front Mol Biosci. 2024; 11:1455415.

PMID: 39703687 PMC: 11656028. DOI: 10.3389/fmolb.2024.1455415.

PRMT5/WDR77 Enhances the Proliferation of Squamous Cell Carcinoma via the ΔNp63α-p21 Axis.

Liang H, Fisher M, Wu C, Ballon C, Sun X, Mills A Cancers (Basel). 2024; 16(22).

PMID: 39594744 PMC: 11592282. DOI: 10.3390/cancers16223789.

Long-Read MDM4 Sequencing Reveals Aberrant Isoform Landscape in Metastatic Melanomas.

Patrick N, Markey M Int J Mol Sci. 2024; 25(17).

PMID: 39273363 PMC: 11395681. DOI: 10.3390/ijms25179415.

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers.

Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H Breast Cancer (Dove Med Press). 2023; 15:785-799.

PMID: 37954171 PMC: 10637385. DOI: 10.2147/BCTT.S430513.

Resistance to PRMT5-targeted therapy in mantle cell lymphoma.

Long M, Koirala S, Sloan S, Brown-Burke F, Weigel C, Villagomez L Blood Adv. 2023; 8(1):150-163.

PMID: 37782774 PMC: 10787272. DOI: 10.1182/bloodadvances.2023010554.

References

Wei T, Juan C, Hisa J, Su L, Lee Y, Chou H . Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade. Cancer Sci. 2012; 103(9):1640-50. PMC: 7659304. DOI: 10.1111/j.1349-7006.2012.02367.x. View

Chen J, Ren Y, Zhang K, Qu J, Hu F, Yan Y . Phosphorylation modification of myofibrillar proteins by sodium pyrophosphate affects emulsion gel formation and oxidative stability under different pH conditions. Food Funct. 2019; 10(10):6568-6581. DOI: 10.1039/c9fo01397k. View

Swerdlow S, Yang W, Zukerberg L, Harris N, Arnold A, Williams M . Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene. Hum Pathol. 1995; 26(9):999-1004. DOI: 10.1016/0046-8177(95)90090-x. View

Li Y, Chitnis N, Nakagawa H, Kita Y, Natsugoe S, Yang Y . PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. Cancer Discov. 2015; 5(3):288-303. PMC: 4355177. DOI: 10.1158/2159-8290.CD-14-0625. View

McConnell B, GREGORY F, Stott F, Hara E, Peters G . Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol. 1999; 19(3):1981-9. PMC: 83991. DOI: 10.1128/MCB.19.3.1981. View

Jansson M, Durant S, Cho E, Sheahan S, Edelmann M, Kessler B . Arginine methylation regulates the p53 response. Nat Cell Biol. 2008; 10(12):1431-9. DOI: 10.1038/ncb1802. View

Sander B . Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin Diagn Pathol. 2011; 28(3):245-55. DOI: 10.1053/j.semdp.2011.02.010. View

Berger S . Out of the jaws of death: PRMT5 steers p53. Nat Cell Biol. 2008; 10(12):1389-90. PMC: 3922054. DOI: 10.1038/ncb1208-1389. View

Liu M, Yao B, Gui T, Guo C, Wu X, Li J . PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression. Theranostics. 2020; 10(10):4437-4452. PMC: 7150477. DOI: 10.7150/thno.42047. View

10.

Yang W, Zukerberg L, Motokura T, Arnold A, Harris N . Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol. 1994; 145(1):86-96. PMC: 1887308. View

11.

Bezzi M, Teo S, Muller J, Mok W, Sahu S, Vardy L . Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery. Genes Dev. 2013; 27(17):1903-16. PMC: 3778243. DOI: 10.1101/gad.219899.113. View

12.

Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y . Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene. 2018; 38(11):1802-1814. DOI: 10.1038/s41388-018-0550-3. View

13.

Yap T, OCarrigan B, Penney M, Lim J, Brown J, De Miguel Luken M . Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2020; 38(27):3195-3204. PMC: 7499606. DOI: 10.1200/JCO.19.02404. View

14.

Beketova E, Owens J, Asberry A, Hu C . PRMT5: a putative oncogene and therapeutic target in prostate cancer. Cancer Gene Ther. 2021; 29(3-4):264-276. PMC: 8514585. DOI: 10.1038/s41417-021-00327-3. View

15.

Mohell N, Alfredsson J, Fransson A, Uustalu M, Bystrom S, Gullbo J . APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015; 6:e1794. PMC: 4669826. DOI: 10.1038/cddis.2015.143. View

16.

Erazo T, Evans C, Zakheim D, Chu E, Refermat A, Asgari Z . TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. Nat Commun. 2022; 13(1):5676. PMC: 9515221. DOI: 10.1038/s41467-022-33137-8. View

17.

Jung D, Jain P, Yao Y, Wang M . Advances in the assessment of minimal residual disease in mantle cell lymphoma. J Hematol Oncol. 2020; 13(1):127. PMC: 7513535. DOI: 10.1186/s13045-020-00961-8. View

18.

Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W . Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. Eur Urol. 2020; 79(2):200-211. DOI: 10.1016/j.eururo.2020.10.029. View

19.

Girardot M, Hirasawa R, Kacem S, Fritsch L, Pontis J, Kota S . PRMT5-mediated histone H4 arginine-3 symmetrical dimethylation marks chromatin at G + C-rich regions of the mouse genome. Nucleic Acids Res. 2013; 42(1):235-48. PMC: 3874197. DOI: 10.1093/nar/gkt884. View

20.

Yap T, Tan D, Terbuch A, Caldwell R, Guo C, Goh B . First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discov. 2020; 11(1):80-91. PMC: 9554790. DOI: 10.1158/2159-8290.CD-20-0868. View